Rett syndrome

VUMC receives $13 million grant to coordinate multisite clinical trial for Rett syndrome treatment

Vanderbilt University Medical Center received a $13 million Department of Defense grant to lead a multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome.

Rett syndrome drug studied at Vanderbilt approved for patients

The first drug to treat the symptoms of Rett syndrome was recently approved, following a Nature Medicine study publishing results from the pivotal phase 3 LAVENDER study led by investigators from Vanderbilt University Medical Center to evaluate efficacy and safety of trofinetide.

Potential Rett syndrome drug shows promising results in phase 3 trial

A potential first-of-its-kind drug to treat the symptoms of Rett syndrome received positive top-line results from a phase 3 trial led by investigators from Vanderbilt University Medical Center to evaluate efficacy and safety.

Treating core Rett syndrome symptoms

A new study published in Neurology reports the drug trofinetide has proven safe and effective in treating core symptoms of Rett syndrome in female children and adolescents.

Caucasian mom and toddler daughter playing in the park

Drug discovery efforts may lead to new Rett syndrome treatments

Vanderbilt University research-ers have relieved symptoms of Rett syndrome in a mouse model with a small molecule that works like the dimmer switch in an electrical circuit.

Rett syndrome expert Neul to speak at Kennedy Center on Friday

Jeffrey Neul, M.D., Ph.D., division head of Child Neurology and vice chair for Developmental Neurosciences at the University of California, San Diego, will present a lecture on Friday, Dec. 16, at Vanderbilt Kennedy Center (VKC).